Glycine vs Lithium Orotate for sleep
Short answer: For sleep, more users report improvement with Lithium Orotate — 100% of 16 reports, versus 87% of 255 for Glycine.
Glycine has 392 meta-analyses and 620 randomized trials on PubMed; Lithium Orotate has 581 and 979.
Based on 695 reports about Glycine and 307 about Lithium Orotate. Not medical advice.
| Glycine Supplement | Lithium Orotate Supplement | |
|---|---|---|
| Users say it helped | 70%helped299 reports · high confidence | 76%helped138 reports · high confidence |
| Verdict | Mostly positive | Mostly positive |
| Research | AResearch: Strong | AResearch: Strong |
| Meta-analyses / RCTs | 392 / 620 | 581 / 979 |
| Mainly used for | ||
| Sleep % reporting improvement | 87% (255) | 100% (16) |
| Mood % reporting improvement | 87% (39) | 92% (108) |
| Anxiety % reporting improvement | 78% (60) | 98% (80) |
| Focus % reporting improvement | 62% (13) | 81% (16) |
| Energy % reporting improvement | 94% (17) | 75% (4) |
| Common side effects | vivid dreams, drowsiness, fatigue, brain fog | brain fog, emotional blunting, sexual dysfunction, drowsiness |
| Typical dose reported | 2 g / daily | 1-2 tablets |
In studies using high-throughput metabolomics, several blood amino acids appear to be consistently associated with the risk of developing type 2 diabetes.
Diabetes Care, 2016 ↗“2 grams with 200mg magnesium before bed gives me crazy good sleep. Crazy vivid dreams.”
Although it is yet to be determined which is more effective between lithium or lecanemab or donanemab, lithium may be more effective than aducanumab. Aducanumab, lecanemab and donanemab do not appear to differ in their effectiveness on cognitive function. Low-dose lithium may be safer than aducanumab, lecanemab and donanemab.
Ageing Res Rev, 2024 ↗“The lithium is absolutely curbing my mania... My social anxiety is 100% gone when I take lithium orotate.”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate